Actualités de la communauté
09.07.2020 Anergis and Virometix Announce Research Collaboration to Use Synthetic Virus-Like Particles for Ultra-Fast Allergy Immunotherapy
– Study is performed at the Helmholtz Centre for Infection Research and supported by a TRANSVAC2 grant
Epalinges, Switzerland, July 09, 2020 – Anergis SA, a company developing Contiguous Overlapping Peptides (COPs) for ultra-fast allergy immunotherapy,and Virometix AG, a company developing a new generation of vaccines and immunotherapeutic drugs, announced today that they have entered into a research collaboration. The study will be conducted at the Helmholtz Centre for Infection Research (HZI, Braunschweig, Germany) as part of TRANSVAC2, the European Network of Vaccine Research and Development funded under the European Union’s Horizon 2020 Research and Innovation Program.
The pre-clinical study program will evaluate the immunogenicity profile of the Anergis peptides designed to treat house dust mite allergy (the Der p 2 COPs) when presented on Virometix’ proprietary Synthetic Virus-Like Particles (SVLP), with or without undisclosed Toll-Like Receptor (TLR) ligands and built-in adjuvants, and will compare the results to Anergis’ Der p 2 COPs with aluminum hydroxide as an extrinsic adjuvant. More broadly, this study will provide information on the applicability of the two technology platforms combined for combatting allergies.
The study was launched at HZI in Q2/2020 and the results are expected by Q4/2020.
“Given the immune-stimulatory properties of the SVLP platform and the extensive clinical experience with Anergis’ COPs, we are convinced that the combination of SVLPs with dust mite COPs represents a highly attractive opportunity to develop a safe and efficacious ultra-fast COP allergy vaccine platform,” commented Alexander Kettner, Head of Research at Anergis.
“We are very excited to start this initial research project with Anergis, a leading company in ultra-fast allergy immunotherapy,” said Anna Sumeray, CEO of Virometix. “We look forward to demonstrating that our proprietary Synthetic Virus-Like Particle (SVLP) technology and vaccine expertise can improve the treatment of allergies.”